Nicolas Poirier
Chief Executive Officer en OSE IMMUNOTHERAPEUTICS .
Fortuna: 1 M $ al 31/03/2024
Perfil
Nicolas Poirier is currently the Chief Executive Officer & Director at OSE Immunotherapeutics SA since 2022.
Previously, he worked as a Project Manager at Effimune SA. Dr. Poirier has a graduate degree from the University of Nantes and Louis Pasteur University, and an undergraduate degree from the Centre d'Etudes Supérieures de Techniques Industrielles.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2022 | 192 802 ( 0.89% ) | 1 M $ | 31/03/2024 |
Cargos activos de Nicolas Poirier
| Empresas | Cargo | Inicio |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Executive Officer | 07/10/2022 |
Antiguos cargos conocidos de Nicolas Poirier.
| Empresas | Cargo | Fin |
|---|---|---|
Effimune SA
 Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Corporate Officer/Principal | - |
Formación de Nicolas Poirier.
| University of Nantes | Graduate Degree |
| Centre d'Etudes Supérieures de Techniques Industrielles | Undergraduate Degree |
| Louis Pasteur University | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Empresas privadas | 1 |
|---|---|
Effimune SA
Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Health Technology |
- Bolsa de valores
- Insiders
- Nicolas Poirier
